Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats

Diabetes

Volumn 46, Issue 5, 1997, Pages 808-813

  Hosokawa, Y A ^a   Leahy, Jack L ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLUCOSE; INSULIN; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; INSULIN RELEASE; INSULIN RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

EID: 0030907293     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.5.808     Document Type: Article

References (49)

1. Leahy JL: Natural history of β-cell dysfunction in NIDDM. Diabetes Care 13:992-1010, 1990
2. Porte D Jr: β-cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
3. Leahy JL, Weir GC: B-cell dysfunction in hyperglycemic rat models: recovery of glucose-induced insulin secretion with lowering of the ambient glucose level. Diabetologia 34:640-647, 1991
4. Kosaka K, Kuzuya T, Akanuma Y, Hagura R: Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment Diabetologia 18:23-28, 1980
5. Leahy JL, Bonner-Weir S, Weir GC: β-cell dysfunction induced by chronic hyperglycemia: current ideas on the mechanism of the impaired glucose-induced insulin secretion. Diabetes Care 15:442-455, 1992
6. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
7. Yki-Järvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
8. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 44:863-870, 1995
9. Prentki M, Corkey BE: Are the β-cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45:273-283, 1996
10. Leahy JL: β-cell dysfunction with chronic hyperglycemia: the "overworked β-cell" hypothesis. Diabetes Rev 4:298-319, 1996
11. Leahy JL, Bumbalo LM, Chen C: Diazoxide causes recovery of β-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 43:173-179, 1994
12. Hosokawa YA, Hosokawa H, Chen C, Leahy JL: Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats: study using GLP-1 (7-37). J Clin Invest 97:180-186, 1996
13. Féry F, Balasse EO: Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM. Diabetes 43:1418-1425, 1994
14. Greenwood RH, Mahler RF, Hales CN: Improvement in insulin secretion in diabetes after diazoxide. Lancet i:444-447, 1976
15. Laedtke T, Schmitz O, Porksen N, Veldhuis J, Butler P: Mechanism of impaired pulsatile insulin secretion in NIDDM? (Abstract). Diabetes 45 (Suppl. 2):40A, 1996
16. Ling Z, Kiekins R, Mahler T, Schuit FC, Pipeleers-Marichal M, Sener A, Klöppel G, Malaisse WJ, Pipeleers DG: Effects of chronically elevated glucose levels on the functional properties of rat pancreatic β-cells. Diabetes 45:1774-1782, 1996
17. Sodoyez J-C, Sodoyez-Goffaux F, Dunbar JC, Foa PP: Reduction in the activity of the pancreatic islets induced in normal rodents by prolonged treatment with derivatives of sulfonylurea. Diabetes 19:603-609, 1970
18. Dunbar JC, Foà PP: An inhibitory effect of tolbutamide and glibenclamide (glyburide) on the pancreatic islets of normal rats. Diabetologia 10:27-35, 1974
19. Shauder P, Arends J, Frerichs H: Onset and reversibility of changes in secretory function and composition of isolated rat pancreatic islets following long-term administration of high or low tolbutamide doses. Metabolism 26:9-15, 1977
20. Schatz H, Laube H, Sieradzki J, Kamenisch W, Pfeiffer EF: Long-term actions of sulfonylureas on (pro-)insulin biosynthesis and secretion. Horm Metab Res 10:23-29, 1978
21. Pittner RA, Albrandt K, Beaumont K, Gaeta LSL, Koda JE, Moore CX, Rittenhouse J, Rink TJ: Molecular physiology of amylin. J Cell Biochem 55S: 19-28, 1994
22. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881-3885, 1987
23. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632, 1987
24. Gedulin B, Cooper GJ, Young AA: Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res Comm 180:782-789, 1991
25. O'Brien TD, Westermark P, Johnson KH: Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40:1701-1706, 1991
26. Inoue K, Hisatomi A, Umeda F, Nawata H: Relative hypersecretion of amylin to insulin from rat pancreas after neonatal STZ treatment. Diabetes 41:723-727, 1992
27. Leahy JL, Cooper HE, Deal DA, Weir GC: Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908-915, 1986
28. Weir GC, Knowlton SD, Martin DB: Glucagon secretion from the perfused rat pancreas: studies with glucose and catecholamines. J Clin Invest 54:1403-1412, 1974
29. Albano JDM, Ekins RP, Maritz G, Turner RC: A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol 70:487-509, 1972
30. Leahy JL: Increased proinsulin/insulin ratio in pancreas extracts of hyperglycemic rats. Diabetes 42:22-27, 1993
31. Chen C, Bumbalo LM, Hosokawa H, Leahy JL: Increased catalytic activity of glucokinase in isolated islets from hyperinsulinemic rats. Diabetes 43:684-689, 1994
32. Leahy JL, Bonner-Weir S, Weir GC: Abnormal glucose regulation of insulin secretion in models of reduced β-cell mass. Diabetes 33:667-673, 1984
33. Giroix M-H, Portha B, Kergoat M, Bailbe D, Picon L: Glucose insensitivity and amino-acid hypersensitivity of insulin release in rats with non-insulin-dependent diabetes: a study with the perfused pancreas. Diabetes 32:445-451, 1983
34. Leahy JL, Weir GC: Unresponsiveness to glucose in a streptozocin model of diabetes: inappropriate insulin and glucagon responses to a reduction of glucose concentration. Diabetes 34:653-659, 1985
35. Bonner-Weir S, Trent DF, Weir GC: Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71:1544-1553, 1983
36. Trent DF, Fletcher DJ, May JM, Bonner-Weir S, Weir GC: Abnormal islet and adipocyte function in young β-cell-deficient rats with near-normoglycemia. Diabetes 33:170-175, 1984
37. Zawalich WS: Regulation of insulin secretion by phosphoinositide-specific phospolipase C and protein kinase C activation. Diabetes Rev 4:160-176, 1996
38. Schatz H, Nierle C, Pfeiffer EF: (Pro-)insulin biosynthesis and release of newly synthesized (pro-)insulin from isolated islets of rat pancreas in the presence of amino acids and sulphonylureas. Eur J Clin Invest 5:477-485, 1975
39. Schatz H, Steinle D, Pfeiffer EF: Long-term actions of sulfonylureas on (pro-)insulin biosynthesis and secretion. I. Lack of evidence for a compensatory increase in (pro)insulin biosynthesis after exposure of isolated pancreatic rat islets to tolbutamide and glibenclamide in vitro. Horm Metab Res 9:457-465, 1977
40. Olson LK, Redmon JB, Towle HC, Robertson RP: Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest 92:514-519, 1993
41. Olson LK, Sharma A, Peshavaria M, Wright CV, Towle HC, Robertson RP, Stein R: Reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to a supraphysiologic glucose concentration is associated with loss of STF-1 transcription factor expression. Proc Natl Acad Sci USA 92:9127-9131, 1995
42. Zangen DH, Miller CP, Habener JF, Weir GC: Transcription factor IDX-1 is reduced in beta cells exposed to chronic hyperglycemia in vivo (Abstract). Diabetes 45 (Suppl. 2):40A, 1996
43. Mulder H, Ahŕen B, Stridsberg M, Sundler F: Nonparallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38:395-402, 1995
44. Mulder H, Ahrén B, Sundler F: Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol Cell Endocrinol 114:101-109, 1995
45. Mulder H, Ahrén B, Sundler F: Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 39:649-657, 1996
46. Hosokawa H, Hosokawa YA, Leahy JL: Upregulated hexokinase activity in isolated islets from diabetic 90% pancreatectomy rats. Diabetes 44:1328-1333, 1995
47. Rhodes CJ, Alarcón C: What beta-cell defect could lead to hyperproinsulinemia in NIDDM?: some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 43:511-517, 1994
48. Leahy JL, Halban PA, Weir GC: Relative hypersecretion of proinsulin in a rat model of non-insulin-dependent diabetes mellitus. Diabetes 40:985-989, 1991
49. Alarcón C, Leahy JL, Schuppin GT, Rhodes CJ: Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non insulin dependent diabetes mellitus. J Clin Invest 95:1032-1039, 1995